DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
December 07 2018 - 7:00AM
DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC)
(TSX‑V:DMA), a clinical stage biopharmaceutical company, announced
today the pricing of its initial public offering in the United
States of 4,100,000 of its common shares at a price to the public
of $4.00 per share. All of the common shares are being offered by
DiaMedica. The common shares are expected to begin trading December
7, 2018 on The Nasdaq Capital Market under the symbol “DMAC.” The
offering is expected to close on December 11, 2018, subject to the
satisfaction of customary closing conditions.
DiaMedica expects to use the net proceeds from
the offering to fund clinical development of DiaMedica’s lead drug
candidate, DM199, to conduct research activities and for working
capital and general corporate purposes.
Craig-Hallum Capital Group LLC is acting as the
sole managing underwriter for the initial public
offering.
A registration statement relating to these
securities has been filed with and was declared effective by the
U.S. Securities and Exchange Commission on December 6, 2018. This
press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The offering is being made only by means of a
prospectus. A copy of the final prospectus related to the offering
may be obtained, when available, from Craig-Hallum Capital Group
LLC at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota
55402, Attention: Equity Capital Markets, by telephone at
612-334-6300, or by e-mail at prospectus@chlm.com.
About DiaMedica
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company focused on developing novel treatments
for neurological and kidney diseases. DiaMedica’s shares are listed
on the TSX Venture Exchange under the trading symbol “DMA” and will
be listed on The Nasdaq Capital Market under the trading symbol
“DMAC.”
Forward-Looking Statements
This press release contains forward-looking
statements and information that are based on the beliefs of
management and reflect our current expectations. When used in this
press release, the words "estimate", "believe", "anticipate",
"intend", "expect", "plan", “will,” "may" or "should" and the
negative of these words or such variations thereon or comparable
terminology are intended to identify forward-looking statements and
information. The forward-looking statements and information in this
press release include statements regarding the expected completion
of the offering, the listing of our common shares on The Nasdaq
Capital Market and the use of proceeds from the offering. Such
statements and information reflect our current view and we
undertake no obligation to update or revise any of these statements
or information. By their nature, forward-looking statements involve
known and unknown risks, uncertainties and other factors which may
cause our actual results, performance or achievements, or other
future events, to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements.
THE FORWARD-LOOKING INFORMATION
CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF
DIAMEDICA AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS
SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE
IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON
THIS INFORMATION AS OF ANY OTHER DATE. WHILE DIAMEDICA MAY ELECT
TO, IT DOES NOT UNDERTAKE TO UPDATE THIS
INFORMATION AT ANY PARTICULAR TIME EXCEPT
AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
For further information:
Paul Papi Vice President of Business Development 2 Carlson
Parkway, Suite 260 Minneapolis, MN 55447 (617) 899-5941
info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024